Extension of impurity profiling on eltrombopag olamine to in-silico predictions: An effort to exploit correlated forced degradation products and known drug-related substances in drug discovery

[Display omitted] •Eltrombopag olamine was subjected to forced degradation and UPLC-ESI-MS studies were performed for major degradation products.•Known drug related substances (RS) were searched from the literature.•m/z values for major forced degradation products were correlated with known RS.•RS w...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of chromatography. B, Analytical technologies in the biomedical and life sciences Analytical technologies in the biomedical and life sciences, 2024-11, Vol.1248, p.124367, Article 124367
Hauptverfasser: Ganorkar, Saurabh B., Bobade, Preeti S., Prabhu, Rakesh C., Lokwani, Deepak K., Shinde, Ranajit N., Telange, Darshan R., Shirkhedkar, Atul A., Vander Heyden, Yvan
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page 124367
container_title Journal of chromatography. B, Analytical technologies in the biomedical and life sciences
container_volume 1248
creator Ganorkar, Saurabh B.
Bobade, Preeti S.
Prabhu, Rakesh C.
Lokwani, Deepak K.
Shinde, Ranajit N.
Telange, Darshan R.
Shirkhedkar, Atul A.
Vander Heyden, Yvan
description [Display omitted] •Eltrombopag olamine was subjected to forced degradation and UPLC-ESI-MS studies were performed for major degradation products.•Known drug related substances (RS) were searched from the literature.•m/z values for major forced degradation products were correlated with known RS.•RS were subjected to Tanimoto similarity, Toxicity - ADME evaluations, and docking.•Justified entry of six RS as potential TPO receptor agonists for drug discovery. The recent pandemic has highlighted the impact of diseases on global health and the economy. The rapid discovery of new hit molecules remains a tough challenge. Pharmaceutical impurity profiling can be linked to drug discovery through the identification of new hits from compounds identified during the analytical profiling. The present study demonstrates this linkage through the extension of the impurity (forced degradation) profiling of eltrombopag (ELT) olamine, a thrombopoietin (TPO) receptor agonist. The drug was exposed to standard degradation and the degradation products were primarily resolved and identified by UPLC-ESI-MS. This led to the identification of five forced degradation products (FDP). Thirty-three other known related substances (RS) of ELT, identified in the literature, were also considered. Molecular similarity checks were performed using Tanimoto/Jaccard's similarity searches. A set of structurally and topologically similar molecules, including ELT and 15 RS, was established and subjected to in-silico toxicity-, absorption-, distribution-, metabolism-, and elimination (ADME) predictions. The RS, predicted with similar or lower toxicity than ELT and a comparable ADME profile, were subjected to molecular docking to trace changes in TPO receptor affinity. The results indicated that five RS had a high Jaccard’s similarity with ELT and higher or comparable docking scores. These compounds, along with few other impurities were predicted to have lower toxicity, better or comparable absorption, distribution, metabolism, and also a better excretion profile than ELT. This justifies their entry as potential novel TPO receptor agonists in drug discovery.
doi_str_mv 10.1016/j.jchromb.2024.124367
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3154252207</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1570023224003763</els_id><sourcerecordid>3128980714</sourcerecordid><originalsourceid>FETCH-LOGICAL-c276t-d0655baccc5eea33d32337c5a14bd7ffd1511bcc26adb1ac3531cb7c78cb01f3</originalsourceid><addsrcrecordid>eNqFkU1v1DAQhiNERT_gJ4B85JKtP-J4ywVVVaGVKnHpoTfLGU8WL4kdbKft_jt-Gg675drT2JrnnXc0b1V9ZHTFKGvPt6st_Ixh7Fac8mbFeCNa9aY6YWslaqHah7flLRWtKRf8uDpNaUspU1SJd9WxuJCNoi0_qf5cP2f0yQVPQk_cOM3R5R2ZYujd4PyGlAYOeTEKkynfwYzOI8mBOF-nwkAoNFoHuQxJX8hlEfR9iHlh8HkagssEQow4mIyWlBaUYnETjTWLaHGzM-REjLfklw9Pntg4b-oXSZq7lI0HTMX0X4tYlyA8Yty9r456MyT8cKhn1f236_urm_rux_fbq8u7Grhqc21pK2VnAEAiGiGs4EIokIY1nVV9b5lkrAPgrbEdMyCkYNApUGvoKOvFWfV5P7bs-nvGlPVYNsBhMB7DnLRgsuGS83Lf11G-vlhTxZqCyj0KMaQUsddTdKOJO82oXmLWW32IWS8x633MRffpYDF3I9r_qpdcC_B1D2A5yaPDqBM4LBe0LiJkbYN7xeIvqvnCUw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3128980714</pqid></control><display><type>article</type><title>Extension of impurity profiling on eltrombopag olamine to in-silico predictions: An effort to exploit correlated forced degradation products and known drug-related substances in drug discovery</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Ganorkar, Saurabh B. ; Bobade, Preeti S. ; Prabhu, Rakesh C. ; Lokwani, Deepak K. ; Shinde, Ranajit N. ; Telange, Darshan R. ; Shirkhedkar, Atul A. ; Vander Heyden, Yvan</creator><creatorcontrib>Ganorkar, Saurabh B. ; Bobade, Preeti S. ; Prabhu, Rakesh C. ; Lokwani, Deepak K. ; Shinde, Ranajit N. ; Telange, Darshan R. ; Shirkhedkar, Atul A. ; Vander Heyden, Yvan</creatorcontrib><description>[Display omitted] •Eltrombopag olamine was subjected to forced degradation and UPLC-ESI-MS studies were performed for major degradation products.•Known drug related substances (RS) were searched from the literature.•m/z values for major forced degradation products were correlated with known RS.•RS were subjected to Tanimoto similarity, Toxicity - ADME evaluations, and docking.•Justified entry of six RS as potential TPO receptor agonists for drug discovery. The recent pandemic has highlighted the impact of diseases on global health and the economy. The rapid discovery of new hit molecules remains a tough challenge. Pharmaceutical impurity profiling can be linked to drug discovery through the identification of new hits from compounds identified during the analytical profiling. The present study demonstrates this linkage through the extension of the impurity (forced degradation) profiling of eltrombopag (ELT) olamine, a thrombopoietin (TPO) receptor agonist. The drug was exposed to standard degradation and the degradation products were primarily resolved and identified by UPLC-ESI-MS. This led to the identification of five forced degradation products (FDP). Thirty-three other known related substances (RS) of ELT, identified in the literature, were also considered. Molecular similarity checks were performed using Tanimoto/Jaccard's similarity searches. A set of structurally and topologically similar molecules, including ELT and 15 RS, was established and subjected to in-silico toxicity-, absorption-, distribution-, metabolism-, and elimination (ADME) predictions. The RS, predicted with similar or lower toxicity than ELT and a comparable ADME profile, were subjected to molecular docking to trace changes in TPO receptor affinity. The results indicated that five RS had a high Jaccard’s similarity with ELT and higher or comparable docking scores. These compounds, along with few other impurities were predicted to have lower toxicity, better or comparable absorption, distribution, metabolism, and also a better excretion profile than ELT. This justifies their entry as potential novel TPO receptor agonists in drug discovery.</description><identifier>ISSN: 1570-0232</identifier><identifier>ISSN: 1873-376X</identifier><identifier>EISSN: 1873-376X</identifier><identifier>DOI: 10.1016/j.jchromb.2024.124367</identifier><identifier>PMID: 39547062</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>absorption ; ADMET ; agonists ; Benzoates - chemistry ; chromatography ; Chromatography, High Pressure Liquid - methods ; Computer Simulation ; Drug Contamination ; Drug Discovery - methods ; drugs ; Eltrombopag olamine ; excretion ; Forced Degradation ; Humans ; Hydrazines - chemistry ; metabolism ; Molecular Docking ; Molecular Docking Simulation ; pandemic ; Pyrazoles - analysis ; Pyrazoles - chemistry ; Pyrazoles - pharmacology ; Related Substances ; Spectrometry, Mass, Electrospray Ionization - methods ; thrombopoietin ; toxicity</subject><ispartof>Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2024-11, Vol.1248, p.124367, Article 124367</ispartof><rights>2024 Elsevier B.V.</rights><rights>Copyright © 2024 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c276t-d0655baccc5eea33d32337c5a14bd7ffd1511bcc26adb1ac3531cb7c78cb01f3</cites><orcidid>0000-0002-3924-6265</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1570023224003763$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39547062$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ganorkar, Saurabh B.</creatorcontrib><creatorcontrib>Bobade, Preeti S.</creatorcontrib><creatorcontrib>Prabhu, Rakesh C.</creatorcontrib><creatorcontrib>Lokwani, Deepak K.</creatorcontrib><creatorcontrib>Shinde, Ranajit N.</creatorcontrib><creatorcontrib>Telange, Darshan R.</creatorcontrib><creatorcontrib>Shirkhedkar, Atul A.</creatorcontrib><creatorcontrib>Vander Heyden, Yvan</creatorcontrib><title>Extension of impurity profiling on eltrombopag olamine to in-silico predictions: An effort to exploit correlated forced degradation products and known drug-related substances in drug discovery</title><title>Journal of chromatography. B, Analytical technologies in the biomedical and life sciences</title><addtitle>J Chromatogr B Analyt Technol Biomed Life Sci</addtitle><description>[Display omitted] •Eltrombopag olamine was subjected to forced degradation and UPLC-ESI-MS studies were performed for major degradation products.•Known drug related substances (RS) were searched from the literature.•m/z values for major forced degradation products were correlated with known RS.•RS were subjected to Tanimoto similarity, Toxicity - ADME evaluations, and docking.•Justified entry of six RS as potential TPO receptor agonists for drug discovery. The recent pandemic has highlighted the impact of diseases on global health and the economy. The rapid discovery of new hit molecules remains a tough challenge. Pharmaceutical impurity profiling can be linked to drug discovery through the identification of new hits from compounds identified during the analytical profiling. The present study demonstrates this linkage through the extension of the impurity (forced degradation) profiling of eltrombopag (ELT) olamine, a thrombopoietin (TPO) receptor agonist. The drug was exposed to standard degradation and the degradation products were primarily resolved and identified by UPLC-ESI-MS. This led to the identification of five forced degradation products (FDP). Thirty-three other known related substances (RS) of ELT, identified in the literature, were also considered. Molecular similarity checks were performed using Tanimoto/Jaccard's similarity searches. A set of structurally and topologically similar molecules, including ELT and 15 RS, was established and subjected to in-silico toxicity-, absorption-, distribution-, metabolism-, and elimination (ADME) predictions. The RS, predicted with similar or lower toxicity than ELT and a comparable ADME profile, were subjected to molecular docking to trace changes in TPO receptor affinity. The results indicated that five RS had a high Jaccard’s similarity with ELT and higher or comparable docking scores. These compounds, along with few other impurities were predicted to have lower toxicity, better or comparable absorption, distribution, metabolism, and also a better excretion profile than ELT. This justifies their entry as potential novel TPO receptor agonists in drug discovery.</description><subject>absorption</subject><subject>ADMET</subject><subject>agonists</subject><subject>Benzoates - chemistry</subject><subject>chromatography</subject><subject>Chromatography, High Pressure Liquid - methods</subject><subject>Computer Simulation</subject><subject>Drug Contamination</subject><subject>Drug Discovery - methods</subject><subject>drugs</subject><subject>Eltrombopag olamine</subject><subject>excretion</subject><subject>Forced Degradation</subject><subject>Humans</subject><subject>Hydrazines - chemistry</subject><subject>metabolism</subject><subject>Molecular Docking</subject><subject>Molecular Docking Simulation</subject><subject>pandemic</subject><subject>Pyrazoles - analysis</subject><subject>Pyrazoles - chemistry</subject><subject>Pyrazoles - pharmacology</subject><subject>Related Substances</subject><subject>Spectrometry, Mass, Electrospray Ionization - methods</subject><subject>thrombopoietin</subject><subject>toxicity</subject><issn>1570-0232</issn><issn>1873-376X</issn><issn>1873-376X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkU1v1DAQhiNERT_gJ4B85JKtP-J4ywVVVaGVKnHpoTfLGU8WL4kdbKft_jt-Gg675drT2JrnnXc0b1V9ZHTFKGvPt6st_Ixh7Fac8mbFeCNa9aY6YWslaqHah7flLRWtKRf8uDpNaUspU1SJd9WxuJCNoi0_qf5cP2f0yQVPQk_cOM3R5R2ZYujd4PyGlAYOeTEKkynfwYzOI8mBOF-nwkAoNFoHuQxJX8hlEfR9iHlh8HkagssEQow4mIyWlBaUYnETjTWLaHGzM-REjLfklw9Pntg4b-oXSZq7lI0HTMX0X4tYlyA8Yty9r456MyT8cKhn1f236_urm_rux_fbq8u7Grhqc21pK2VnAEAiGiGs4EIokIY1nVV9b5lkrAPgrbEdMyCkYNApUGvoKOvFWfV5P7bs-nvGlPVYNsBhMB7DnLRgsuGS83Lf11G-vlhTxZqCyj0KMaQUsddTdKOJO82oXmLWW32IWS8x633MRffpYDF3I9r_qpdcC_B1D2A5yaPDqBM4LBe0LiJkbYN7xeIvqvnCUw</recordid><startdate>20241101</startdate><enddate>20241101</enddate><creator>Ganorkar, Saurabh B.</creator><creator>Bobade, Preeti S.</creator><creator>Prabhu, Rakesh C.</creator><creator>Lokwani, Deepak K.</creator><creator>Shinde, Ranajit N.</creator><creator>Telange, Darshan R.</creator><creator>Shirkhedkar, Atul A.</creator><creator>Vander Heyden, Yvan</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7S9</scope><scope>L.6</scope><orcidid>https://orcid.org/0000-0002-3924-6265</orcidid></search><sort><creationdate>20241101</creationdate><title>Extension of impurity profiling on eltrombopag olamine to in-silico predictions: An effort to exploit correlated forced degradation products and known drug-related substances in drug discovery</title><author>Ganorkar, Saurabh B. ; Bobade, Preeti S. ; Prabhu, Rakesh C. ; Lokwani, Deepak K. ; Shinde, Ranajit N. ; Telange, Darshan R. ; Shirkhedkar, Atul A. ; Vander Heyden, Yvan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c276t-d0655baccc5eea33d32337c5a14bd7ffd1511bcc26adb1ac3531cb7c78cb01f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>absorption</topic><topic>ADMET</topic><topic>agonists</topic><topic>Benzoates - chemistry</topic><topic>chromatography</topic><topic>Chromatography, High Pressure Liquid - methods</topic><topic>Computer Simulation</topic><topic>Drug Contamination</topic><topic>Drug Discovery - methods</topic><topic>drugs</topic><topic>Eltrombopag olamine</topic><topic>excretion</topic><topic>Forced Degradation</topic><topic>Humans</topic><topic>Hydrazines - chemistry</topic><topic>metabolism</topic><topic>Molecular Docking</topic><topic>Molecular Docking Simulation</topic><topic>pandemic</topic><topic>Pyrazoles - analysis</topic><topic>Pyrazoles - chemistry</topic><topic>Pyrazoles - pharmacology</topic><topic>Related Substances</topic><topic>Spectrometry, Mass, Electrospray Ionization - methods</topic><topic>thrombopoietin</topic><topic>toxicity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ganorkar, Saurabh B.</creatorcontrib><creatorcontrib>Bobade, Preeti S.</creatorcontrib><creatorcontrib>Prabhu, Rakesh C.</creatorcontrib><creatorcontrib>Lokwani, Deepak K.</creatorcontrib><creatorcontrib>Shinde, Ranajit N.</creatorcontrib><creatorcontrib>Telange, Darshan R.</creatorcontrib><creatorcontrib>Shirkhedkar, Atul A.</creatorcontrib><creatorcontrib>Vander Heyden, Yvan</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>AGRICOLA</collection><collection>AGRICOLA - Academic</collection><jtitle>Journal of chromatography. B, Analytical technologies in the biomedical and life sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ganorkar, Saurabh B.</au><au>Bobade, Preeti S.</au><au>Prabhu, Rakesh C.</au><au>Lokwani, Deepak K.</au><au>Shinde, Ranajit N.</au><au>Telange, Darshan R.</au><au>Shirkhedkar, Atul A.</au><au>Vander Heyden, Yvan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Extension of impurity profiling on eltrombopag olamine to in-silico predictions: An effort to exploit correlated forced degradation products and known drug-related substances in drug discovery</atitle><jtitle>Journal of chromatography. B, Analytical technologies in the biomedical and life sciences</jtitle><addtitle>J Chromatogr B Analyt Technol Biomed Life Sci</addtitle><date>2024-11-01</date><risdate>2024</risdate><volume>1248</volume><spage>124367</spage><pages>124367-</pages><artnum>124367</artnum><issn>1570-0232</issn><issn>1873-376X</issn><eissn>1873-376X</eissn><abstract>[Display omitted] •Eltrombopag olamine was subjected to forced degradation and UPLC-ESI-MS studies were performed for major degradation products.•Known drug related substances (RS) were searched from the literature.•m/z values for major forced degradation products were correlated with known RS.•RS were subjected to Tanimoto similarity, Toxicity - ADME evaluations, and docking.•Justified entry of six RS as potential TPO receptor agonists for drug discovery. The recent pandemic has highlighted the impact of diseases on global health and the economy. The rapid discovery of new hit molecules remains a tough challenge. Pharmaceutical impurity profiling can be linked to drug discovery through the identification of new hits from compounds identified during the analytical profiling. The present study demonstrates this linkage through the extension of the impurity (forced degradation) profiling of eltrombopag (ELT) olamine, a thrombopoietin (TPO) receptor agonist. The drug was exposed to standard degradation and the degradation products were primarily resolved and identified by UPLC-ESI-MS. This led to the identification of five forced degradation products (FDP). Thirty-three other known related substances (RS) of ELT, identified in the literature, were also considered. Molecular similarity checks were performed using Tanimoto/Jaccard's similarity searches. A set of structurally and topologically similar molecules, including ELT and 15 RS, was established and subjected to in-silico toxicity-, absorption-, distribution-, metabolism-, and elimination (ADME) predictions. The RS, predicted with similar or lower toxicity than ELT and a comparable ADME profile, were subjected to molecular docking to trace changes in TPO receptor affinity. The results indicated that five RS had a high Jaccard’s similarity with ELT and higher or comparable docking scores. These compounds, along with few other impurities were predicted to have lower toxicity, better or comparable absorption, distribution, metabolism, and also a better excretion profile than ELT. This justifies their entry as potential novel TPO receptor agonists in drug discovery.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>39547062</pmid><doi>10.1016/j.jchromb.2024.124367</doi><orcidid>https://orcid.org/0000-0002-3924-6265</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 1570-0232
ispartof Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2024-11, Vol.1248, p.124367, Article 124367
issn 1570-0232
1873-376X
1873-376X
language eng
recordid cdi_proquest_miscellaneous_3154252207
source MEDLINE; Elsevier ScienceDirect Journals
subjects absorption
ADMET
agonists
Benzoates - chemistry
chromatography
Chromatography, High Pressure Liquid - methods
Computer Simulation
Drug Contamination
Drug Discovery - methods
drugs
Eltrombopag olamine
excretion
Forced Degradation
Humans
Hydrazines - chemistry
metabolism
Molecular Docking
Molecular Docking Simulation
pandemic
Pyrazoles - analysis
Pyrazoles - chemistry
Pyrazoles - pharmacology
Related Substances
Spectrometry, Mass, Electrospray Ionization - methods
thrombopoietin
toxicity
title Extension of impurity profiling on eltrombopag olamine to in-silico predictions: An effort to exploit correlated forced degradation products and known drug-related substances in drug discovery
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T03%3A50%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Extension%20of%20impurity%20profiling%20on%20eltrombopag%20olamine%20to%20in-silico%20predictions:%20An%20effort%20to%20exploit%20correlated%20forced%20degradation%20products%20and%20known%20drug-related%20substances%20in%20drug%20discovery&rft.jtitle=Journal%20of%20chromatography.%20B,%20Analytical%20technologies%20in%20the%20biomedical%20and%20life%20sciences&rft.au=Ganorkar,%20Saurabh%20B.&rft.date=2024-11-01&rft.volume=1248&rft.spage=124367&rft.pages=124367-&rft.artnum=124367&rft.issn=1570-0232&rft.eissn=1873-376X&rft_id=info:doi/10.1016/j.jchromb.2024.124367&rft_dat=%3Cproquest_cross%3E3128980714%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3128980714&rft_id=info:pmid/39547062&rft_els_id=S1570023224003763&rfr_iscdi=true